Prothena Highlights Advances in Protein Dysregulation Therapies for Neurodegenerative Diseases in Latest Presentation
I'm PortAI, I can summarize articles.
Prothena Corporation plc has highlighted its advancements in therapies for neurodegenerative diseases, focusing on its late-stage pipeline. Key developments include prasinezumab for Parkinson’s disease entering Phase 3 trials by 2025 with Roche, coramitug for ATTR-CM in Phase 3 with Novo Nordisk, and BMS-986446 for Alzheimer’s in Phase 2 with results expected by 2027. The company collaborates with Roche, Bristol Myers Squibb, and Novo Nordisk. This overview was presented in their latest presentation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments